Analysis of Clinical Laboratory Tests for Benign Prostatic Hyperplasia_West China Medical Journal

Authors：

 LIAOHong ¹ , WUYi ¹ , ZHANGPeng ² , LIZeng ¹ , XIAOYing-ming ¹ , ZHANGLin ³ , ZHOUBin ³

1. Department of Urology, Sichuan Cancer Hospital, Chengdu, Sichuan 610041, P. R. China;
2. Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
3. Staff Room of Medicologal Genetics, College of Basic and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

Keywords：

Prostatic hyperplasia; Fasting insulin; Total cholesterol; Triglyceride; Body mass index

DOI：

10.7507/1002-0179.20140621

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the relationship between some clinical laboratory tests, such as levels of fasting insulin (FINS), triglyceride (TG) and total cholesterol (TC), and benign prostatic hyperplasia (BPH). Methods A total of 146 male patients were included in this study. All the subjects were from the clinic of West China Hospital and Sichuan Cancer Hospital from January 2012 to July 2013. Serum FINS, TG, TC and prostate specific antigen (PSA) were tested, respectively. Prostate volume (PV) was measured by ultrasound. Results FINS, PAS and annual prostate growth rate increased significantly in the large PV group compared with the small PV group (P<0.01). There was no significant association of PV with body mass index and other laboratory tests like serum TC and TG. PV and annual prostate growth rate increased significantly in the group of high FINS level compared with the group of low FINS level (P<0.01). PV was positively correlated with FINS (r=0.159, P<0.05); and annual prostate growth rate was positively correlated with FINS (r=0.201, P<0.05). Conclusion Hyperinsulinism may play an important role in the pathogenesis of BPA.

Citation： LIAOHong, WUYi, ZHANGPeng, LIZeng, XIAOYing-ming, ZHANGLin, ZHOUBin. Analysis of Clinical Laboratory Tests for Benign Prostatic Hyperplasia. West China Medical Journal, 2014, 29(11): 2059-2062. doi: 10.7507/1002-0179.20140621 Copy

1.	Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia[J]. Eur Urol, 2001, 39(2):151-158.
2.	Dahle SE, Chokkalingam AP, Gao YT, et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia[J]. J Urol, 2002, 168(2):599-604.
3.	Ozden C, Ozdal OL, Urgancioglu G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia[J]. Eur Urol, 2007, 51(1):199-203.
4.	刘颖, 屈晓冰, 董莉妮, 等. 老年人良性前列腺增生症与胰岛素抵抗[J]. 中华老年医学杂志, 2010, 29(11):896-898.
5.	Kwon H, Kang HC, Lee JH. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms[J]. Urology, 2013, 81(6):1325-1329.
6.	Parsons JK, Sarma AV, Mcvary K, et al. Obesity and benign prostatic hyperplasia:clinical connections, emerging etiological paradigms and future directions[J]. J Urol, 2009, 182(Suppl 6):S27-S31.
7.	Vikram A, Jena G, Ramarao P. Insulin-resistance and benign prostatic hyperplasia:the connection[J]. Eur J Pharmacol, 2010, 641(2/3):75-81.
8.	Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats:linking hyperinsulinemia with benign prostate hyperplasia[J]. Prostate, 2010, 70(1):79-89.
9.	Nandeesha H, Koner BC, Dorairajan LN, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia[J]. Clin Chim Acta, 2006, 370(1/2):89-93.
10.	Qu X, Huang Z, Meng X, et al. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients[J]. Int Urol Nephrol, 2014, 46(3):499-504.
11.	Wallner LP, Hollingsworth JM, Dunn RL, et al. Hyperglycemia, hyperinsulinemia, insulin resistance, and the risk of BPH/LUTS severity and progression over time in community dwelling black men:the Flint Men's Health Study[J]. Urology, 2013, 82(4):881-886.
12.	Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome:an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement[J]. Circulation, 2005, 112(17):2735-2752.
13.	Park YW, Kim SB, Kwon H, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome[J]. Urology, 2013, 82(3):674-679.
14.	Gao Y, Wang M, Zhang H, et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey[J]. Urology, 2012, 79(1):194-201.
15.	Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with henign prostatic hyperplasia[J]. J Clin Endocrinol Metab, 2006, 91(7):2562-2568.
16.	Holliger S, Schneider E, Madersbachers S, et al. Relation of body mass index (BMI) with the risk of developing BPH[J]. Eur Urol Suppl, 2002, 1(1):60.
17.	陈振勇, 陈晓春, 黄文广, 等. 胰岛素抵抗与良性前列腺增生的相关性研究[J]. 中华老年医学杂志, 2010, 29(11):888-890.
18.	何家扬, 王伟. 代谢综合征与前列腺增生症[J]. 现代泌尿外科杂志, 2009, 14(2):81-83.
19.	Hammarsten J, Damber JE, Karlsson M, et al. Insulin and free oestradiol are Independent risk factors for benign prostatic hyperplasia[J]. Prostate Cancer Prostatic Dis, 2009, 12(2):160-165.
20.	Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-1 and prostate cancer risk:aprospective[J]. Science, 1998, 279(5350):563-566.
21.	Wang Z, Olumi AF. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia[J]. Differentiation, 2011, 82(4/5):261-271.

1. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia[J]. Eur Urol, 2001, 39(2):151-158.
2. Dahle SE, Chokkalingam AP, Gao YT, et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia[J]. J Urol, 2002, 168(2):599-604.
3. Ozden C, Ozdal OL, Urgancioglu G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia[J]. Eur Urol, 2007, 51(1):199-203.
4. 刘颖, 屈晓冰, 董莉妮, 等. 老年人良性前列腺增生症与胰岛素抵抗[J]. 中华老年医学杂志, 2010, 29(11):896-898.
5. Kwon H, Kang HC, Lee JH. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms[J]. Urology, 2013, 81(6):1325-1329.
6. Parsons JK, Sarma AV, Mcvary K, et al. Obesity and benign prostatic hyperplasia:clinical connections, emerging etiological paradigms and future directions[J]. J Urol, 2009, 182(Suppl 6):S27-S31.
7. Vikram A, Jena G, Ramarao P. Insulin-resistance and benign prostatic hyperplasia:the connection[J]. Eur J Pharmacol, 2010, 641(2/3):75-81.
8. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats:linking hyperinsulinemia with benign prostate hyperplasia[J]. Prostate, 2010, 70(1):79-89.
9. Nandeesha H, Koner BC, Dorairajan LN, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia[J]. Clin Chim Acta, 2006, 370(1/2):89-93.
10. Qu X, Huang Z, Meng X, et al. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients[J]. Int Urol Nephrol, 2014, 46(3):499-504.
11. Wallner LP, Hollingsworth JM, Dunn RL, et al. Hyperglycemia, hyperinsulinemia, insulin resistance, and the risk of BPH/LUTS severity and progression over time in community dwelling black men:the Flint Men's Health Study[J]. Urology, 2013, 82(4):881-886.
12. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome:an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement[J]. Circulation, 2005, 112(17):2735-2752.
13. Park YW, Kim SB, Kwon H, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome[J]. Urology, 2013, 82(3):674-679.
14. Gao Y, Wang M, Zhang H, et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey[J]. Urology, 2012, 79(1):194-201.
15. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with henign prostatic hyperplasia[J]. J Clin Endocrinol Metab, 2006, 91(7):2562-2568.
16. Holliger S, Schneider E, Madersbachers S, et al. Relation of body mass index (BMI) with the risk of developing BPH[J]. Eur Urol Suppl, 2002, 1(1):60.
17. 陈振勇, 陈晓春, 黄文广, 等. 胰岛素抵抗与良性前列腺增生的相关性研究[J]. 中华老年医学杂志, 2010, 29(11):888-890.
18. 何家扬, 王伟. 代谢综合征与前列腺增生症[J]. 现代泌尿外科杂志, 2009, 14(2):81-83.
19. Hammarsten J, Damber JE, Karlsson M, et al. Insulin and free oestradiol are Independent risk factors for benign prostatic hyperplasia[J]. Prostate Cancer Prostatic Dis, 2009, 12(2):160-165.
20. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-1 and prostate cancer risk:aprospective[J]. Science, 1998, 279(5350):563-566.
21. Wang Z, Olumi AF. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia[J]. Differentiation, 2011, 82(4/5):261-271.

Previous Article
Clinical Observation of Docetaxel Combined with Oxaliplatin Regimen for Advanced Gastric Cancer
Next Article
Application of Acute Non-isovolemic Hemodilution for Spinal Surgery

West China Medical Journal

Analysis of Clinical Laboratory Tests for Benign Prostatic Hyperplasia

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content